Genolution Inc. of Seoul at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Genolution Inc.

Rm 506, 11 Beobwon-ro 11-gil, Songpa-gu, 05836 Seoul
Korea, Republic
Telephone +82 2 3400 0151
Fax +82 2 449 8671

Hall map

MEDICA 2019 hall map (Hall 3): stand E92

Fairground map

MEDICA 2019 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.07  Other diagnostics

Our products

Product category: Other diagnostics


Nextractor® is automatic extraction system for rapid isolation of DNA or RNA from a variety samples.
Using of Nextractor® can purify up to 48 samples, saving valuable time and labor in your lab.
Also it offers a high throughput processing and yields.

Fully Automated Extraction
-Walk away system

High Throughput
-48 Speciments at one run
-48 Extractions in 10 minutes

Pre-filled Catridge type of Reagent
-Single, 8, 24 Extraction Cartridge
-All Cartridge can be used simultaneously without and change of Hardware and software format

-UV Lamp/Auto door Lock

7’Touch Screen based User interface
-Easy to operate without training
-Pre-programmed and User define protocols


More Less

Product category: Other diagnostics

Renovated agriculture by RNA

RNA interference(RNAi) is a novel method of sequence-specifically blocking gene function that works by introducing into cells with short sequences of RNA that match part of a target organism's gene sequence.
RNA interference works in the cytoplasm of the cell; thus it does not genetically modify the organism. It can block an organism's production of an essential protein, suppress or modify various genetic traits in an organism without changing the genetic make-up of the organism. It has been well known that long dsRNA (200-800bp) can initiate RNAi in plant, worms, insect, and even shrimp. Thus, dsRNA may be a new raw material for herbicide, insecticide, anti-fungal and anti-viral applications for agricultural as well as environmental applications. Because of its sequence specificity, it can also be designed to have no toxicity to unintended organisms. An RNA approach, especially when using long dsRNAs, can also minimize the development of insecticidal or herbicidal resistance, and be a key objective in the development of agricultural control agents.

In contrast to the difficulty of delivering RNA in humans and animals, an RNAi gene silencing effect by dsRNA has been shown in plants, insects, worms, and crustaceans by a simple spray, injection, or feeding.
Even just spraying crude extracts of bacterially expressed dsRNA or in vitro transcribed dsRNA can be used to protect plants against several viral infections. Also a dsRNA corresponding to an essential insect gene is sprayed on a crop. As the insect is feeding on the crop, it takes up the dsRNA which in turn eliminates or reduces an essential protein in the insect leading to the death of the insect and protection of the crop plant. Another approach might be to make a dsRNA corresponding to a herbicide-resistance gene in weeds thus rendering the weed susceptible to the herbicide. dsRNAs have thus emerged as an innovative pest and weed control reagent.

More Less

About us

Company details

Genolution Inc. was established in 2006 by Gi-Ok Kim, current CEO, to facilitate the sale and manufacturing of IVD products - mainly focusing on Molecular Diagnostics, RNAi services and dsRNA research for the prevention of breeding and extermination. After obtaining permission for Research Institute in 2007, Genolution invested in R&D, which resulted in a serial success of RNA synthesis in 2008 and RNAi validation in 2009 and started RNAi services in the 2nd half of 2009, which is one of the major businesses at the moment.

Afterwards, having secured ISO 13845 and permission to manufacture medical instruments in July and August 2013, Genolution set up a manufacturing factory for nucleic acid extraction instrument and launched the Nextractor in January 2014, which is considered to be one of the most efficient DNA/RNA extractors. In September 2014, Genolution started to sell 6 nucleic acid reagents including the STD extraction kit and, in August 2015, Genolution made a successful listing on the KONEX market in Korea Stock Exchange and accomplished a groundbreaking turnaround by achieving KRW 16.6MM of operating income and KRW 81.4MM of net profit in 2015.

In the 1st half of 2016, Genolution entered into contracts with several overseas distributors in China and Italy to ignite dramatic increases in sales and a considerable increase in export is expected to be realized in the near future. The company set up an ambitious long term goal of “Being a Global Life Science Group” and is making every effort to achieve this goal.

More Less